AstraZeneca/Forest to start five Phase III trials tackling superbugs
This article was originally published in Scrip
Executive Summary
AstraZeneca and Forest Laboratories are to start a five-trial Phase III programme investigating the potential of ceftazidime/avibactam (CAZ-AVI) in treating hospitalised patients with serious Gram-negative bacterial infections including complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI), "an unmet need", AstraZeneca told Scrip.